Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review

    December 2022 in “ Pharmacological Reviews ”
    Edris Choupani, Mohammad Mahmoudi Gomari, Saeed Zanganeh, Sherko Nasseri, Kaveh Haji-Allahverdipoor, Neda Rostami, Yaeren Hernandez, Safa Najafi, Neda Saraygord‐Afshari, Arshad Hosseini
    TLDR Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.
    The review discussed the potential of targeting androgen receptors (AR) in treating triple-negative breast cancer (TNBC), which accounted for 15% to 20% of breast malignancies and was known for its aggressiveness and resistance to hormone therapies. It highlighted the development of new AR inhibitors and advanced techniques like CRISPR/Cas9 and nanotechnology to enhance targeted therapy efficiency. The review emphasized the promise of combining AR-targeted therapies with other pathways like CDK4/6 and PI3K for AR+ TNBC patients. Despite these advancements, the role of AR in TNBC remained not well understood, and further research was needed to establish AR inhibitors as a viable treatment option for breast cancer.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results